SUSTAINED RESPONSE OFF-TREATMENT WITH THROMOBOPOIETIN RECEPTOR AGONISTS AND FOSTAMATINIB: A 15-YEAR SINGLE-CENTER REAL-WORLD EXPERIENCE IN IMMUNE THROMOBOCYTOPENIA WITH IDENTIFICATION OF BIOLOGICAL PREDICTORS (SIE 2026) - Oct 6, 2026 - Abstract #DP049; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Treat- ments included eltrombopag, romiplostim, avatrombopag, fostamatinib, or sequential combinations. Elevated LDH levels may identify patients less likely to sustain SROT, suggesting a potential role as a biomarker of disease activity and treatment-free remission. Prospective validation is warranted."
Clinical • Real-world • Real-world evidence • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
|
|
V. Innao; O. Bianco; V. Leotta; M. Di Giorgio; A. Barbagallo; A. Gorgone; M. Salerno; G. Uccello; A. Todaro; F. Lo Presti; R. Calogero; V. Uccellatore; U. Consoli
|